GlassScriptPhysician profile
Tamrat Bekele
NPI 1376545947
$7,757.27
in general payments reported to CMS, 2019-2025
31 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $802 · 2021: $1,000 · 2022: $1,131 · 2023: $1,406 · 2024: $1,033 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,784 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,783.77 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,301.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,191.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $940.06 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $696.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $583.27 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $454.19 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $433.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.54 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.82 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $163.41 | 2019-2022 | |
| Lundbeck LLC | $156.12 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $111.73 | 2025 | Rexulti |
| Amarin Pharma, INC. | $104.71 | 2019-2021 | |
| Abbott Laboratories | $102.46 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $91.04 | 2019-2023 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $83.17 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $82.89 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.06 | 2022 | |
| Astellas Pharma US INC | $76.64 | 2019-2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $73.26 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $40.29 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $36.25 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $34.91 | 2024 | Ultomiris |
| Radius Health, INC. | $32.62 | 2020-2021 | |
| Exact Sciences Corporation | $22.21 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.63 | 2025 | Voquezna |
| Allergan, INC. | $15.19 | 2020 | |
| Philips North America LLC | $13.53 | 2019 | |
| Axonics, INC. | $13.43 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamrat Bekele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.